Kalaris Therapeutics, Inc. Common Stock (KLRS) is a publicly traded Healthcare sector company. As of May 21, 2026, KLRS trades at $4.86 with a market cap of $112.78M and a P/E ratio of -10.39. KLRS moved +3.09% today. Year to date, KLRS is -40.95%; over the trailing twelve months it is +45.05%. Its 52-week range spans $2.14 to $12.90. Analyst consensus is strong buy with an average price target of $15.75. Rallies surfaces KLRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own KLRS include Redmile Group. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Kalaris Therapeutics, Inc. Common Stock.
| Metric | Value |
|---|---|
| Price | $4.86 |
| Market Cap | $112.78M |
| P/E Ratio | -10.39 |
| EPS | $-0.46 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.90 |
| 52-Week Low | $2.14 |
| Volume | 10 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-10.86M |
| Gross Margin | 0.00% |
5 analysts cover KLRS: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.75.